Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Bristol-Myers Squibb
Robert J Motzer; Paul Russo; Viktor Grünwald; Yoshihiko Tomita; Bogdan Zurawski; Omi Parikh; Sebastiano Buti; Philippe Barthélémy; Jeffrey C Goh; Dingwei Ye; Alejo Lingua; Jean-Baptiste Lattouf; Laurence Albigès; Saby George; Brian Shuch; Jeffrey Sosman; Michael Staehler; Sergio Vázquez Estévez; Burcin Simsek; Julia Spiridigliozzi; Aleksander Chudnovsky; Axel Bex
Department of Global Biometrics and Data Science, Bristol Myers Squibb, Princeton, NJ, USA.